The emphasis of DZNE Ulm is on translational research. This approach aims to transfer scientific results into clinical application as quickly as possible so that patients can benefit from it. The integration of Ulm into the nationwide clinical research network of the DZNE, which conducts inter-site studies, provides a very good basis for this.
In Ulm, which has long been a centre of topnotch neurological research, the DZNE will focus on rare nerve diseases such as Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD) and Huntington's disease. To this end, it cooperates with the University of Ulm, the University Hospital and the University and Rehabilitation Clinics (RKU). The new site is to develop diagnostic and therapeutic procedures and to accompany scientific findings as quickly as possible into clinical practice.
With its clinical study centre and patient registers for ALS and Huntington's disease, Ulm also has an outstanding infrastructure for medical research. In the next few years, the staff of the DZNE in Ulm will grow to up to 50 people. The Federal Government and the State of Baden-Württemberg intend to invest jointly in the development of the site. Scientists who are already working in Ulm are also included. The employees of the DZNE will initially use existing university premises. In the medium term, a separate research building is to be built.